In a deal that could be worth more than £1.1bn, British firm confirms sale of division to US drugmaker
AstraZeneca has agreed to sell its antibiotics division to Pfizer, the US drugs company that failed in its bid to buy the group in a takeover battle two years ago.
In a deal that could be worth more than $1.5bn (£1.1bn), the British pharmaceutical group said it would sell its late-stage small molecule antibiotics business in most markets outside the US to Pfizer.
Continue reading...from Mergers and acquisitions | The Guardian http://ift.tt/2bzaeSq
No comments:
Post a Comment